IL326758A - טיפול בסרטן מוצק עם לזופוקסיפן - Google Patents

טיפול בסרטן מוצק עם לזופוקסיפן

Info

Publication number
IL326758A
IL326758A IL326758A IL32675826A IL326758A IL 326758 A IL326758 A IL 326758A IL 326758 A IL326758 A IL 326758A IL 32675826 A IL32675826 A IL 32675826A IL 326758 A IL326758 A IL 326758A
Authority
IL
Israel
Prior art keywords
lasofoxifene
pharmaceutically acceptable
acceptable salt
functional derivative
cancer
Prior art date
Application number
IL326758A
Other languages
English (en)
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of IL326758A publication Critical patent/IL326758A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL326758A 2023-08-21 2024-08-21 טיפול בסרטן מוצק עם לזופוקסיפן IL326758A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363520872P 2023-08-21 2023-08-21
US202463567843P 2024-03-20 2024-03-20
US202463636638P 2024-04-19 2024-04-19
PCT/US2024/043261 WO2025043004A1 (en) 2023-08-21 2024-08-21 Treatment of solid cancer with lasofoxifene

Publications (1)

Publication Number Publication Date
IL326758A true IL326758A (he) 2026-04-01

Family

ID=92710824

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326758A IL326758A (he) 2023-08-21 2024-08-21 טיפול בסרטן מוצק עם לזופוקסיפן

Country Status (8)

Country Link
EP (1) EP4766362A1 (he)
KR (1) KR20260068765A (he)
CN (1) CN121941497A (he)
AU (1) AU2024328571A1 (he)
IL (1) IL326758A (he)
MX (1) MX2026002142A (he)
TW (1) TW202523288A (he)
WO (1) WO2025043004A1 (he)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CA2479924C (en) 2002-03-28 2008-07-15 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
CN115844877B (zh) * 2017-01-10 2024-07-23 浙江嘉驰医药开发有限公司 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
CN117771239A (zh) * 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
GB202116903D0 (en) * 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Also Published As

Publication number Publication date
TW202523288A (zh) 2025-06-16
AU2024328571A1 (en) 2026-03-12
CN121941497A (zh) 2026-04-28
MX2026002142A (es) 2026-06-01
WO2025043004A1 (en) 2025-02-27
EP4766362A1 (en) 2026-07-01
KR20260068765A (ko) 2026-05-14

Similar Documents

Publication Publication Date Title
GB202116903D0 (en) Lasofoxifene treatment of aromatase-resistant er+ cancer
HUE073220T2 (hu) KAT6 inhibitor és kombinációk mellrák kezelésére
GB202107994D0 (en) Treatment of cancer
IL326327A (he) טיפול בסרטן הערמונית
IL314687A (he) טיפול בסרטן
AU2024328571A1 (en) Treatment of solid cancer with lasofoxifene
CA3302440A1 (en) Treatment of solid cancer with lasofoxifene
GB202218395D0 (en) Cancer therapy
HK40117011A (en) Lasofoxifene treatment of aromatase-resistant er+ cancer
AU2021372815A9 (en) Combination treatment of cancer
GB202311976D0 (en) Treatment of cancer
IL316821A (he) טיפול בסרטן עם nuc-7738
GB202218181D0 (en) Treatment of cancer
GB202201803D0 (en) Treatment of Cancer
IL314034A (he) טיפול בסרטן השחלה באמצעות נירוגססטט
IL320448A (he) שיטות לטיפול בסרטן באמצעות סוטורסיב
GB202315849D0 (en) Improved cancer treatment
GB202303784D0 (en) Cancer treatment
GB202217305D0 (en) Cancer treatment
GB202211123D0 (en) Cancer treatment
GB202210038D0 (en) Cancer treatment
GB202206948D0 (en) Cancer treatment
GB202018062D0 (en) Treatment of cancer
GB202008037D0 (en) Treatment of cancer
GB202004514D0 (en) Treatment of Immunosuppressive Cancer